


PHARMACEUTICAL 2018

NeuroBo Pharmaceuticals Inc. Rank 317 of 349





PHARMACEUTICAL 2018

NeuroBo Pharmaceuticals Inc. Rank 317 of 349

The relative strengths and weaknesses of NeuroBo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuroBo Pharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 84% points. The greatest weakness of NeuroBo Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 391% points.

The company's Economic Capital Ratio, given in the ranking table, is -770%, being 493% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	19,009
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,390
Liabilities, Non-Current	3.0
Other Assets	8.0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	8,683
Other Net Income	-291
Property and Equipment	0
Research and Development	22,686
Revenues	0
Selling, General and Administrative Expense	10,438

Output Variable	Value in 1000 USD
Assets	19,017
Liabilities	15,076
Expenses	33,124
Stockholders Equity	3,941
Net Income	-33,415
Comprehensive Net Income	-33,415
Economic Capital Ratio	-770%